Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
117
2
7

Year Published

2013
2013
2017
2017

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 150 publications
(129 citation statements)
references
References 15 publications
3
117
2
7
Order By: Relevance
“…In addition to the mechanisms involving a change in the cellular composition of the neovascular membrane (pericyte coverage) and in the effects on the retinal architecture (fibrosis), the loss of activity has been partially attributed to tachyphylaxis or to increased tolerance. 22 At present the dilemma of when and how to change medications after their efficacy has diminished has not been addressed. [23][24][25][26] Aflibercept is the last anti-VEGF drug that has been approved for the treatment of naive CNV associated with AMD, based on the efficacy demonstrated in the VIEW trials.…”
Section: Discussionmentioning
confidence: 99%
“…In addition to the mechanisms involving a change in the cellular composition of the neovascular membrane (pericyte coverage) and in the effects on the retinal architecture (fibrosis), the loss of activity has been partially attributed to tachyphylaxis or to increased tolerance. 22 At present the dilemma of when and how to change medications after their efficacy has diminished has not been addressed. [23][24][25][26] Aflibercept is the last anti-VEGF drug that has been approved for the treatment of naive CNV associated with AMD, based on the efficacy demonstrated in the VIEW trials.…”
Section: Discussionmentioning
confidence: 99%
“…Tachyphylaxis has been discussed to be important in the development of a resistance to intravitreal injections. 16,17 However, the mechanisms are not clear. In some cases, high doses of ranibizumab (2.0 mg opposed to the regularly used 0.5 mg) could yield a response in patients with persisting SRF or IRF under monthly injections of ranibizumab.…”
Section: Discussionmentioning
confidence: 99%
“…The term tachyphylaxis is defined as a diminished therapeutic response to a drug following repeated administration over time and is one mechanism by which treatment resistance to anti-VEGF therapy could occur [10]. One study showed that 10 % (6/58) of eyes treated with bevacizumab developed treatment resistance after a median time of 100 weeks and a median of eight injections; high dose intravitreal bevacizumab (2.50 mg) did not restore therapeutic response in these patients [11].…”
Section: Tachyphylaxis or Tolerancementioning
confidence: 99%